Spyre Therapeutics Hits Record High on Positive SPY002 Trial Results

In a move that bolsters optimism within the biotechnology sector, Spyre Therapeutics announced positive clinical trial results, prompting analysts to upgrade their outlook for the company. According to reports, BTIG raised its price target for the stock to $112, suggesting a potential 34% upside from current levels. This bullish sentiment follows the Phase 2 trial of SPY002, a treatment for ulcerative colitis, which met its primary goals with 33% of patients achieving clinical remission.

This progress comes amid intense competition in the immunology-focused pharmaceutical space, as Spyre aims to differentiate itself with a strong safety and efficacy profile. Compared to sector peers like Roivant Sciences, which previously reported robust results in similar immunological fields, BTIG's new valuation reflects growing confidence in SPY002's market potential. Per market data, the company's market capitalization has grown to $5.05 billion following the announcement of these successful results.

From a technical perspective, SYRE shares closed at $83.58 (close June 15, 2026) after hitting a new yearly high of $84.69 during the session. Traders are now watching for sustained momentum above support levels near $80.79. Looking ahead, investors are awaiting the U.S. Inflation Rate (CPI) data on June 10, 2026, which could impact risk appetite across the growth and biotech sectors.